The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 13, 2024

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 12, 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Nov 7, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 22, 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Oct 17, 2024

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 11, 2024

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

May 22, 2024

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Mar 22, 2024
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...17
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap